Skip to content

Resveratrol in multiple sclerosis

Survey the effect of resveratrol supplementation on some oxidative stress and inflammatory biomarkers, fatigue scale, fasting blood sugar and lipid profile in patients with Multiple Sclerosis.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230315057731N1
Enrollment
60
Registered
2023-05-12
Start date
2023-04-21
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: 500 mg of resveratrol (in the form of two capsules made by Raha Company) for 8 weeks. Intervention 2: Control group: tow placebo per day (made by Raha company) for

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: The disease is diagnosed according to McDonald's criteria. EDSS score 0 to 5 The clinical condition of the patient is relapse-remittance. Age 18 to 65 years

Exclusion criteria

Exclusion criteria: The patient consumes alcohol, tobacco or drugs. Use of antioxidant supplements and hormonal treatments. Body mass index(BMI) higher than 30. Any progressive or autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
Tumor Necrosis Factor Alpha (TNF-a). Timepoint: Before and two months after intervention. Method of measurement: ELISA.;MDA. Timepoint: Before and two months after intervention. Method of measurement: ELISA.;Fatigue scale. Timepoint: Before and two months after intervention. Method of measurement: MFIS questionnaire.

Secondary

MeasureTime frame
Fasting Blood Sugar. Timepoint: Before and two months after intervention. Method of measurement: Enzymatic.;Lipid Profile (TC , TG, HDL, LDL). Timepoint: Before and two months after intervention. Method of measurement: Enzymatic.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Keramatzadeh

Ahvaz University of Medical Sciences

Sarakeramatzadeh@yahoo.com+98 61 3571 5794

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026